20 April 2021 | News
The new platform expedites digitally-enabled collection of prepared blood and cells to help treat challenging diseases and conditions
Photo Credit: Terumo
Terumo Blood and Cell Technologies and CSL Plasma announced a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and the introduction of the new platform is subject to U.S. Food and Drug Administration device clearance.
Terumo Blood and Cell Technologies is a medical technology company. Its software enables the collection of prepared blood and cells to help treat challenging diseases and conditions. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation, based in Tokyo.
CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in U.S., Europe and China. Plasma collected at CSL Plasma centers is used by CSL Behring for the purpose of manufacturing and delivering its life-saving therapies to people suffering from serious and rare diseases in more than 100 countries. CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. The parent company, CSL Limited, headquartered in Melbourne, Australia delivers its life-saving therapies to people in more than 100 countries.
Plasma is a key ingredient for therapies crucial to treating patients around the world suffering from a host of life-threatening conditions, such as primary immune deficiencies, hereditary angioedema, autoimmune diseases, hemophilia and inherited respiratory disease. Plasma is also commonly given to patients experiencing trauma, burns and organ transplant surgeries.